Although approaches for analyzing and exploiting vast amounts of genomic data promise to improve and accelerate the drug discovery and development process, major bottlenecks remain at every step in this process, from target identification and validation, to lead discovery and optimization, to preclinical testing, to clinical development. This report examines where the bottlenecks are, what companies and technologies are addressing these inefficiencies, and what future breakthroughs are needed. It includes case studies of major companies (e.g., Bayer, CuraGen, Millennium, Vertex Pharmaceuticals) and their efforts to break through bottlenecks, examines major business models, and maps the milestones needed to be achieved for success. Also examined are business and dealmaking trends as revealed through an analysis of data from Cambridge Healthtech Institute's Drug Discovery and Development Deals Database. The activities of more than 80 companies are reviewed, and insights from more than 20 industry experts are included.
View Cart
